A molecular diagnostics company with a novel in-vitro diagnostic test to detect colorectal cancer requested that PRA Health Sciences help transition a full-service study crucial to its premarket approval (PMA) filing. The previous CRO had missed site and patient enrollment milestones, potentially jeopardizing the study’s PMA filing and Food and Drug Administration (FDA) approval.